Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes [0.03%]
基于病理分期和表皮生长因子受体分子亚型的非小细胞肺癌（NSCLC）的分子和临床差异性研究
Dayoung Yoon,Ji Won Lee,Byoung Chul Cho et al.
Dayoung Yoon et al.
Background: While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a cornerstone of therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC), resistance remains a major clinical cha...
Development of a deep learning model based on computed tomography automatic segmentation to assist in selecting optimal time-to-surgery and dissected lymph node count for non-small cell lung cancer patients undergoing neoadjuvant immunotherapy and chemotherapy: a multicenter study [0.03%]
基于CT自动分割的深度学习模型在免疫治疗联合新辅助化疗非小细胞肺癌患者手术时机及淋巴结采样数目选择中的应用价值研究：多中心研究
Junfeng Zhao,Ying Li,Jiaxuan Chen et al.
Junfeng Zhao et al.
Background: Many studies have confirmed the efficacy of neoadjuvant immunotherapy combined with chemotherapy (NICT) in treating patients with non-small cell lung cancer (NSCLC). However, the optimal time-to-surgery (TTS) ...
Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study [0.03%]
基于PD-L1表达水平的纳武利尤单抗联合低剂量伊匹利姆玛或单独纳武利尤单抗治疗非小细胞肺癌患者的疗效和安全性：一项多中心回顾性队列研究
Akio Nomura,Takeshi Masuda,Kiyofumi Shimoji et al.
Akio Nomura et al.
Background: The standard first-line treatment for patients with driver mutation-negative non-small cell lung cancer (NSCLC) is chemotherapy and immunotherapy, including chemotherapy plus anti-programmed death-1 (PD-1)/pro...
A novel maximum wall thickness (Tmax) category for cystic lung adenocarcinomas: a retrospective study focusing on pathological invasiveness and prognosis [0.03%]
囊性肺腺癌的最大壁厚度(Tmax)分型及其侵袭性和预后的回顾性研究
Beinuo Wang,Jin Pu,Jian Zhou et al.
Beinuo Wang et al.
Background: Cystic lung adenocarcinoma (CLA) is a major subtype of cystic lung cancer (CLC). Clinical T staging for CLA is ambiguous due to cystic components. This issue impedes precise assessment. Previous research has c...
Lightweight hybrid foundation model for lung cancer prognosis based on low-dose chest X-ray images [0.03%]
基于低剂量胸部X光图像的肺癌预后轻量级混合基础模型
Helen Haile Hayeso,Zenebe Markos Lonseko,Fahad Mushabbab G Alotaibi et al.
Helen Haile Hayeso et al.
Background: Lung cancer (LC) is the leading cause of cancer mortality worldwide. Accurate prognosis in vulnerable populations, particularly in low-resource settings remains challenging with high radiation dose of standard...
Prognostic implications of dominant lesion misidentification in multiple primary lung cancer [0.03%]
多原发肺癌诊断主导病灶误判的预后影响分析
Bowen Zhao,Xiaoyun Su,Yu Huang et al.
Bowen Zhao et al.
Background: Surgical resection remains the cornerstone of treatment for multiple primary lung cancer (MPLC). Given that the dominant lesion (DL) primarily determines the prognosis of patients with MPLC, accurate identific...
Real-time breath metabolomics as catalyst for personalized lung cancer diagnostics: prospective matched case-control trial (LUCAbreath) [0.03%]
实时呼吸代谢组学作为个性化肺癌诊断的催化剂：前瞻性匹配病例对照试验（LUCAbreath）
Felix Schmidt,Diego M Baur,Patrick Baumgartner et al.
Felix Schmidt et al.
Background: Exhaled breath analysis offers notable advantages as a non-invasive method for obtaining biological information from lung cancer patients. However, since the 1980s, its successful translation into clinical pra...
Effect of cold ischemia time and storage temperature on anaplastic lymphoma kinase (ALK) expression in surgically resected lung cancer specimens [0.03%]
冷缺血时间和保存温度对肺癌手术切除标本中间变性淋巴瘤激酶(ALK)表达的影响
Ryuichi Yoshimura,Naoki Yanagawa,Noriyuki Yamada et al.
Ryuichi Yoshimura et al.
Background: Driver gene mutations in lung cancer serve as essential targets for personalized therapy. Ensuring the quality of resected specimens is crucial for accurate diagnosis. This study aimed to evaluate the correlat...
Erratum: KRAS under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition [0.03%]
KRAS成为攻击目标：涉及G12C抑制剂和XPO1抑制的靶向治疗的最新进展（勘误）
Editorial Office
Editorial Office
[This corrects the article DOI: 10.21037/tlcr-2025-665.]. © AME Publishing Company.
Published Erratum
Translational lung cancer research. 2026 Mar 23;15(3):68. DOI:10.21037/tlcr-2026b-01 2026
Jiaying Deng,Zhengfei Zhu
Jiaying Deng
This study reviewed radiotherapy-related studies on lung cancer presented at the 2025 major international conferences [American Society of Clinical Oncology (ASCO), World Conference on Lung Cancer (WCLC), European Society for Medical Oncolo...